Findings from the BIG 3-07/TROG 07.01 DCIS Trial (Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study) has been recognised on a global scale in leading medical journal, The Lancet. You can read
The RAVES trial treating prostate cancer Participating in a clinical trial, like the TROG Cancer Research RAVES trial, often means more than just accessing new technology that could increase treatment and quality of life outcomes. For people like James, it’s about using an understandably challenging situation to help others.
Ductal carcinoma in situ (DCIS) of the breast is characterised by abnormal cells in the milk ducts which have not spread into the breast tissue. An international study (BIG 3-07/TROG 07.01) shows that after breast conserving surgery, higher radiation doses to the part of the breast where the DCIS
Paving the way for success in prostate cancer treatment, TROG Cancer Research are helping to reduce common side effects and the length of treatment with the TROG 15.01 SPARK Trial. The clinical trial, led by Professor Paul Keall and Professor Jarad Martin, proposes the use of kilovoltage intrafraction monitoring (KIM) alongside stereotactic body radiotherapy (SBRT) to provide
Prostate cancer is one of the most common cancers amongst men, with one in six men diagnosed before their 85th birthday (Cancer Australia). In fact, in 2019 alone over 19,000 men in Australia were diagnosed with prostate cancer. The high rate of prostate cancer diagnosis in Australian men has led this to
New research by the University of New South Wales (UNSW), presented at the Clinical Oncology Society of Australia’s (COSA) Annual Scientific Meeting (ASM) found that increased use of radiation therapy for prostate cancer patients could save lives. Up to 41 early deaths in NSW alone could be prevented each
